Michael Weller - Concepedia

Author

Michael Weller

Also Known As

Christian La Fougere, Colin Watts, E Le Rhun, Gerd Maass, Holger Moch, J. Georges, Keisuke Ueki, M P I Weller, M P Weller, M WELLER

2.8K

Publications

162.2K

Citations

174

H-Index

437

Concepts

All Affiliations

University Hospital of Zurich University of Tübingen University of Zurich Heidelberg University German Cancer Research Center

About

Michael Weller is an author at University Hospital of Zurich specializing in medicine, glioma, and neuro-oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	40	86	8.6K
2	Engineering	11	12	596
3	Arts	1	1	19
4	Education	1	1	13
5	Language Studies	1	1	36

Michael Weller

833

Publications

124.1K

Citations

146

H-Index

Page 1

	Year	Citations
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Roger Stupp, Warren Mason, Martin J. van den Bent, New England Journal of Medicine	2005	21K
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Roger Stupp, Monika E. Hegi, Warren Mason, The Lancet Oncology 5-Year AnalysisNeuro-oncologyOncologyRadiation TherapyAdjuvant Temozolomide	2009	7.7K
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia, New England Journal of Medicine	2005	7.1K
DNA methylation-based classification of central nervous system tumours David Capper, David Jones, Martin Sill, Nature Neuro-oncologyDna Methylation-based ClassificationMedicineEpigenetic ChangeDna Methylation	2018	2.9K
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma Roger Stupp, Sophie Taillibert, Andrew A. Kanner, JAMA	2017	2.5K
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Christiane A. Opitz, Ulrike Litzenburger, Felix Sahm, Nature Tumor BiologyOncogenic AgentMedicineEndogenous Tumour-promoting LigandReceptor (Biochemistry)	2011	1.8K
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma David A. Reardon, Alba A. Brandes, Antonio Omuro, JAMA Oncology	2020	1.4K
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Christian Hartmann, Jochen Meyer, David Capper, Acta Neuropathologica Neuro-oncologySomatic VariantDiffuse GliomasPathologyNeuroscience	2009	1.1K
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Wolfgang Wick, Michael Platten, Christoph Meisner, The Lancet Oncology Neuro-oncologyTemozolomide ChemotherapyMalignant AstrocytomaRadiation TherapyMedicine	2012	1.1K
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K

Page 1